These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27880014)

  • 1. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
    Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
    Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells.
    Holz C; Niehr F; Boyko M; Hristozova T; Distel L; Budach V; Tinhofer I
    Radiother Oncol; 2011 Oct; 101(1):158-64. PubMed ID: 21665310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
    Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
    Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.
    Hashimoto A; Hashimoto S; Ando R; Noda K; Ogawa E; Kotani H; Hirose M; Menju T; Morishige M; Manabe T; Toda Y; Ishida S; Sabe H
    PLoS One; 2011; 6(8):e23359. PubMed ID: 21858086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbon ion irradiation withstands cancer stem cells' migration/invasion process in Head and Neck Squamous Cell Carcinoma (HNSCC).
    Moncharmont C; Guy JB; Wozny AS; Gilormini M; Battiston-Montagne P; Ardail D; Beuve M; Alphonse G; Simoëns X; Rancoule C; Rodriguez-Lafrasse C; Magné N
    Oncotarget; 2016 Jul; 7(30):47738-47749. PubMed ID: 27374096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.
    Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Okamoto K; Calderwood SK; Kozaki KI
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1267-1272. PubMed ID: 30017201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
    Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
    J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
    Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
    Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?
    Wagenblast J; Baghi M; Mörtel S; Hirth D; Thron L; Arnoldner C; Gstöttner W; May A; Hambek M
    Oncol Rep; 2009 Jul; 22(1):171-6. PubMed ID: 19513520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
    Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
    Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
    [No Abstract]   [Full Text] [Related]  

  • 13. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
    Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
    Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients.
    Sato H; Hatanaka KC; Hatanaka Y; Hatakeyama H; Hashimoto A; Matsuno Y; Fukuda S; Sabe H
    Cell Commun Signal; 2014 Mar; 12():17. PubMed ID: 24621372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
    Ansell A; Jedlinski A; Johansson AC; Roberg K
    J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy.
    Guy JB; Méry B; Ollier E; Espenel S; Vallard A; Wozny AS; Simonet S; Lauret A; Battiston-Montagne P; Ardail D; Alphonse G; Rancoule C; Rodriguez-Lafrasse C; Magné N
    Sci Rep; 2017 Sep; 7(1):12207. PubMed ID: 28939847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
    J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.